Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy

Trial Profile

Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy

Discontinued
Phase of Trial: Phase 0

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms BTXADMPPNP
  • Most Recent Events

    • 06 Aug 2017 Status changed from recruiting to discontinued due to enrolling failure (lack of participants)
    • 05 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top